Luminera Derm

Luminera Derm Overview

Luminera Derm is an R&D company and manufacturer of injectable medical devices in the field of aesthetic medicine. Crystalys is a calcium hydroxyapatite-based injectable dermal filler designed to restore facial volume and natural contours by promoting generation and deposition of natural collagen, the body's physiological soft-tissue filler. HArmonyCa is designed to restore facial volume and correct facial deficiencies by promoting the generation of natural endogenous collagen. Hydryalix is a sterile, transparent, cross-linked hyaluronic acid injectable filler. Hydryal is an injectable, non-cross-linked hyaluronic acid clear gel, designed to enhance skin hydration and restore skin vitality. All Luminera products strictly comply with ISO9001 and ISO13485 standards.

Latest News

Oct 18, 2020 · en.globes.co.il

growth-positive

Looking $100 million

American pharmaceutical giant AbbVie has announced the acquisition of Israeli aesthetic medicine company Luminera Derm. The acquisition price is estimated at $100 million. Luminera Derm, which develops and markets subcutaneous injection products, has annual revenue in the tens of millions of dollars. The acquisition will be made through Allergan, one of the worlds leading aesthetic medicine companies. Luminera Derms leading innovation, HArmonyCa, is one of the main reasons for the acquisition. The acquisition will provide Luminera Derm with the capital needed to conduct clinical trials and expand its product portfolio. The company had faced challenges due to the COVID-19 pandemic, but has seen a rebound in revenue as markets reopened. The acquisition is expected to have a positive impact on AbbVies growth.

AcquisitionExpand

Oct 8, 2020 · en.globes.co.il

growth-positive

AbbVie buys Israeli aesthetic medicine co Luminera

AbbVies unit Allergan Aesthetics has entered into an agreement to acquire Israeli company Luminera Derm, which has a portfolio and pipeline of dermal filler products. The financial details of the acquisition were not disclosed, but it is believed to be several hundred million dollars. The acquisition is expected to contribute to AbbVies growth in the aesthetics market and enhance its product offering for healthcare professionals and patients globally. Lumineras lead product, HArmonyCa, is a differentiated dermal filler that combines hyaluronic acid with calcium hydroxyapatite. The acquisition is a strategic move for AbbVie to strengthen its position in the dermal filler category.

Acquisition

Funding

Team Members

2

Employees: 11-50

Web & Social Links

Locations

Bat Sheva Street 1, Lod, Israel

Photos & Videos

3 item(s)

Luminera Derm Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info